169 related articles for article (PubMed ID: 27077672)
1. Effect of Recombinant Human Growth Hormone and Rosiglitazone for HIV-Associated Abdominal Fat Accumulation on Adiponectin and other Markers of Inflammation.
Leung V; Chiu YL; Kotler DP; Albu J; Zhu YS; Ham K; Engelson ES; Hammad H; Christos P; Donovan DS; Ginsberg HN; Glesby MJ
HIV Clin Trials; 2016 Mar; 17(2):55-62. PubMed ID: 27077672
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial.
Glesby MJ; Albu J; Chiu YL; Ham K; Engelson E; He Q; Muthukrishnan V; Ginsberg HN; Donovan D; Ernst J; Lesser M; Kotler DP
PLoS One; 2013; 8(4):e61160. PubMed ID: 23593417
[TBL] [Abstract][Full Text] [Related]
3. The effect of recombinant human growth hormone with or without rosiglitazone on hepatic fat content in HIV-1-infected individuals: a randomized clinical trial.
Kotler DP; He Q; Engelson ES; Albu JB; Glesby MJ
Antivir Ther; 2016; 21(2):107-16. PubMed ID: 25536669
[TBL] [Abstract][Full Text] [Related]
4. Long-term high-physiological-dose growth hormone reduces intra-abdominal fat in HIV-infected patients with a neutral effect on glucose metabolism.
Hansen BR; Haugaard SB; Jensen FK; Jensen JE; Andresen L; Iversen J; Andersen O
HIV Med; 2010 Apr; 11(4):266-75. PubMed ID: 20002779
[TBL] [Abstract][Full Text] [Related]
5. Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics.
Ghanim H; Dhindsa S; Aljada A; Chaudhuri A; Viswanathan P; Dandona P
J Clin Endocrinol Metab; 2006 Sep; 91(9):3553-8. PubMed ID: 16804037
[TBL] [Abstract][Full Text] [Related]
6. Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone.
Macallan DC; Baldwin C; Mandalia S; Pandol-Kaljevic V; Higgins N; Grundy A; Moyle GJ
HIV Clin Trials; 2008; 9(4):254-68. PubMed ID: 18753120
[TBL] [Abstract][Full Text] [Related]
7. Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.
Stanley TL; Falutz J; Mamputu JC; Soulban G; Potvin D; Grinspoon SK
AIDS; 2011 Jun; 25(10):1281-8. PubMed ID: 21516030
[TBL] [Abstract][Full Text] [Related]
8. The effects of recombinant human growth hormone (rhGH) supplementation on adipokines and C-reactive protein in obese subjects.
Albert SG; Haas MJ; Mooradian AD
Growth Horm IGF Res; 2007 Feb; 17(1):19-25. PubMed ID: 17118687
[TBL] [Abstract][Full Text] [Related]
9. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.
Kadoglou NP; Kapelouzou A; Tsanikidis H; Vitta I; Liapis CD; Sailer N
Exp Clin Endocrinol Diabetes; 2011 Feb; 119(2):63-8. PubMed ID: 21031343
[TBL] [Abstract][Full Text] [Related]
10. Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial.
van Wijk JP; de Koning EJ; Cabezas MC; op't Roodt J; Joven J; Rabelink TJ; Hoepelman AI
Ann Intern Med; 2005 Sep; 143(5):337-46. PubMed ID: 16144892
[TBL] [Abstract][Full Text] [Related]
11. Effects of a combination of rhGH and metformin on adiponectin levels in patients with metabolic syndrome.
Herrmann BL; Saller B; Stratmann M; Berg C; Mann K; Janssen OE
Horm Metab Res; 2005 Jan; 37(1):49-52. PubMed ID: 15702440
[TBL] [Abstract][Full Text] [Related]
12. Low-dose growth hormone therapy reduces inflammation in HIV-infected patients: a randomized placebo-controlled study.
Lindboe JB; Langkilde A; Eugen-Olsen J; Hansen BR; Haupt TH; Petersen J; Andersen O
Infect Dis (Lond); 2016; 48(11-12):829-37. PubMed ID: 27417288
[TBL] [Abstract][Full Text] [Related]
13. Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy.
Sutinen J; Kannisto K; Korsheninnikova E; Fisher RM; Ehrenborg E; Nyman T; Virkamäki A; Funahashi T; Matsuzawa Y; Vidal H; Hamsten A; Yki-Järvinen H
Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E941-9. PubMed ID: 14749206
[TBL] [Abstract][Full Text] [Related]
14. The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in hiv-positive patients on highly-active antiretroviral therapy (HAART).
Schindler K; Rieger A; Tura A; Gmeinhardt B; Touzeau-Römer V; Haider D; Pacini G; Ludvik B
Horm Metab Res; 2009 Jul; 41(7):573-9. PubMed ID: 19322744
[TBL] [Abstract][Full Text] [Related]
15. Discrepancies in the regulation of plasma adiponectin and TNF-alpha levels and adipose tissue gene expression in obese African Americans with glucose intolerance: a pilot study using rosiglitazone.
Osei K; Gaillard T; Cook C; Kaplow J; Bullock M; Schuster D
Ethn Dis; 2005; 15(4):641-8. PubMed ID: 16259488
[TBL] [Abstract][Full Text] [Related]
16. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection.
Engelson ES; Glesby MJ; Mendez D; Albu JB; Wang J; Heymsfield SB; Kotler DP
J Acquir Immune Defic Syndr; 2002 Aug; 30(4):379-91. PubMed ID: 12138344
[TBL] [Abstract][Full Text] [Related]
17. Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio.
Mulligan K; Yang Y; Wininger DA; Koletar SL; Parker RA; Alston-Smith BL; Schouten JT; Fielding RA; Basar MT; Grinspoon S
AIDS; 2007 Jan; 21(1):47-57. PubMed ID: 17148967
[TBL] [Abstract][Full Text] [Related]
18. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
[TBL] [Abstract][Full Text] [Related]
19. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome.
Samaha FF; Szapary PO; Iqbal N; Williams MM; Bloedon LT; Kochar A; Wolfe ML; Rader DJ
Arterioscler Thromb Vasc Biol; 2006 Mar; 26(3):624-30. PubMed ID: 16357312
[TBL] [Abstract][Full Text] [Related]
20. Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study.
Majuri A; Santaniemi M; Rautio K; Kunnari A; Vartiainen J; Ruokonen A; Kesäniemi YA; Tapanainen JS; Ukkola O; Morin-Papunen L
Eur J Endocrinol; 2007 Feb; 156(2):263-9. PubMed ID: 17287417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
